Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Dexmedetomidine hydrochloride eqv Dexmedetomidine
ORION PHARMA (SG) PTE. LTD.
N05CM18
INFUSION, SOLUTION CONCENTRATE
Dexmedetomidine hydrochloride eqv Dexmedetomidine 100 mcg/ml
INTRAVENOUS
Prescription Only
Orion Corporation, Orion Pharma
ACTIVE
2023-04-25
1 1. NAME OF THE MEDICINAL PRODUCT Dexdor concentrate for solution for infusion 100 micrograms/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of concentrate contains dexmedetomidine hydrochloride equivalent to 100 micrograms dexmedetomidine. Each 2 ml ampoule contains 200 micrograms of dexmedetomidine. Each 2 ml vial contains 200 micrograms of dexmedetomidine. Each 4 ml vial contains 400 micrograms of dexmedetomidine. Each 10 ml vial contains 1000 micrograms of dexmedetomidine. The concentration of the final solution after dilution should be either 4 micrograms/ml or 8 micrograms/ml. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). The concentrate is a clear, colourless solution, pH 4.5 – 7.0 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3). For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION FOR SEDATION OF ADULT ICU (INTENSIVE CARE UNIT) PATIENTS REQUIRING A SEDATION LEVEL NOT DEEPER THAN AROUSAL IN RESPONSE TO VERBAL STIMULATION (CORRESPONDING TO RICHMOND AGITATION-SEDATION SCALE (RASS) 0 TO -3). For hospital use only. Dexdor should be administered by healthcare professionals skilled in the management of patients requiring intensive care. Posology Patients already intubated and sedated may switch to dexmedetomidine with an initial infusion rate of 0.7 micrograms/kg/h which may then be adjusted stepwise within the dose range 0.2 to 1.4 micrograms/kg/h in order to achieve the desired level of sedation, depending on the patient’s response. A lower starting infusion rate should be considered for frail patients. Dexmedetomidine is 2 very potent and the infusion rate i Read the complete document